Effects of Long-Term Type I Interferon on the Arterial Wall and Smooth Muscle Progenitor Cells Differentiation | Arteriosclerosis, Thrombosis, and Vascular Biology
Hypoxia abrogates antichlamydial properties of IFN-γ in human fallopian tube cells in vitro and ex vivo | PNAS
-5.jpg "SARS-CoV-2 inhibits the cellular response to interferon")
SARS-CoV-2 inhibits the cellular response to interferon
Type I Interferons and Interferon Regulatory Factors Regulate TNF-Related Apoptosis-Inducing Ligand (TRAIL) in HIV-1-Infected Macrophages | PLOS ONE
An alternative mouse model of SARS-CoV-2 infection
Effective nebulization of interferon-γ using a novel vibrating mesh | Respiratory Research | Full Text
IFN-γ Is Produced by Polymorphonuclear Neutrophils in Human Uterine Endometrium and by Cultured Peripheral Blood Polymorphonuclear Neutrophils | The Journal of Immunology
Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size - ScienceDirect
Discoordinate Surface Expression of IFN-γ-Induced HLA Class II Proteins in Nonprofessional Antigen-Presenting Cells with Absence of DM and Class II Colocalization | The Journal of Immunology
Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics - The Lancet Microbe
Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain | Journal of Neuroscience
Transgenic mice in influenza research – risk assessment and vaccine development - Healthcare industry
How Zika Infection Drives Fetal Demise | HHMI
Neurons produce type I interferon during viral encephalitis | PNAS
Seeking an Early COVID-19 Drug, Researchers Look to Interferons | The Scientist Magazine®
Aggregation-prone peptides modulate interferon gamma functionality in naturally occurring protein nanoparticles | bioRxiv
Severe COVID-19 Cases Linked to Genes, Autoimmunity, and Interferon Disruption
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer | Science Immunology
Interferon adds no clinical benefit for hospitalized patients with COVID-19
_-_1200_width.jpg "Early interferon therapy may mitigate COVID-19 severity")
Early interferon therapy may mitigate COVID-19 severity
UM Today | Rady Faculty of Health Sciences | UM immunologist applies interferon expertise to COVID-19
Interferon does not improve outcomes for hospitalized adults with COVID-19 | National Institutes of Health (NIH)
Interferon Archives - Baylor College of Medicine Blog Network
Frontiers | Single-Cell Analyses of Human Eosinophils at High Resolution to Understand Compartmentalization and Vesicular Trafficking of Interferon -Gamma
Activation and evasion of type I interferon responses by SARS-CoV-2 | Nature Communications
Could interferon drugs help fight COVID-19?
Interferon-Induced Transmembrane Protein 3 Blocks Fusion of Diverse Enveloped Viruses by Altering Mechanical Properties of Cell Membranes | ACS Nano
